Beginner's Mind

Beginner's Mind

Download on the App Store

All Beginner's Mind episodes

  • #41: Christoph Lengauer - Can Your Biotech Survive If Its Lead Drug Fails?

    A biotech can spend years getting its first drug into the clinic. If that program fails, what can the team build next?

    In this 2021 Beginner’s Mind conversation, Christoph Lengauer, then a partner at Third Rock Ventures, explains how Blueprint Medicines built what he calls a “product engine” to discover and develop drug candidates repeatedly. He walks me through how Third Rock tested ideas for two or three years before launching companies, why it typically committed $50–80 million at Series A, and why its partners stepped into operating roles.

    We also get into the decisions founders face as they scale. Why can the investors who help you raise your first $3 million make the next round harder? When is a smaller ownership stake worth taking? And why did Thrive Earlier Detection choose a sale to Exact Sciences over an IPO? For Lengauer, that last decision came down to who could get the test into the hands of primary care physicians.

    “You always pick the A team.” — Christoph Lengauer

    TIMESTAMPS

    (00:00) What founders need to know before starting a biotech
    (01:33) From cancer genetics at Johns Hopkins to building biotech companies
    (05:12) How Blueprint Medicines built beyond its first drug
    (08:48) Why Lengauer would back the stronger team over the stronger idea
    (10:31) What changes when your pitch starts with the patient
    (13:40) What an IPO makes possible for a biotech
    (16:45) Why Third Rock chose Nasdaq
    (20:42) Why the first $3 million can be easier to raise in Europe
    (25:40) How early investors can make the next round harder
    (30:20) How Third Rock built companies before writing the Series A check
    (35:24) First movers, founder dilution, and the size of the pie
    (39:48) Why Thrive Earlier Detection chose a sale over an IPO
    (45:24) How investors came to see value in diagnostics and rare disease
    (49:46) What the 2021 biotech funding boom looked like from the inside
    (52:49) Drug pricing and the challenge of getting medicines to patients
    (01:02:14) Where genomics, prevention, and early detection could take medicine

    Follow Beginner’s Mind for conversations on how founders and investors build companies around hard science.

    Join the newsletter at https://lsg2g.substack.com/

    Send us Fan Mail

    Support the show

    Join the Podcast Newsletter: Link

    Your Next Move: Link

    1 hr 8 min
  • #40: beaconsmind - Max Weiland About Starting a Company and get it to a Dual Listing in only 6 years

    In history, most of the time, humans needed to provide everything they needed to make a living for themselves. Trading goods were part of life but didn’t take up most of the world’s population’s time.

    Industrialization changed the job profiles, the needs of workers, and the availability of goods.

    In this century, many people in the western world have jobs to provide services and get what they need for getting through the day in shops. Since I can think I mostly get my shopping done on Saturday.

    It is an event for the whole family, and often I invite friends for the coffee breaks to get a bit of socializing.

    In March 2020, the pandemic shifted a lot of commerce towards the internet and trained the western world's population to adopt online shopping.

    Whenever such a Black Swan Event happens, the consumer’s expectations shift as a result of such a dramatic experience.

    What new expectations will appear once the pandemic is over and consumers come back to real-life shopping more often?

    Max Weiland is working on solutions for such challenges with his team since 2014.

    About beaconsmind

    Founded in 2015 in Switzerland, beaconsmind is a pioneer in location-based marketing (LBM) software for retail chains. beaconsmind helps retailers run successful location-based marketing campaigns.

    By fitting stores with Bluetooth beacons that precisely locate and identify customers and integrating its Software Suite, beaconsmind opens a brand-new channel for retailers to interact with their customers, fundamentally transforming the shopping experience. Thanks to its solution, retailers can converge digital and physical shopping and address the convenience gaps.

    Consumers increasingly expect the convenience of the online shopping experience at the POS. In that regard, LBM is a proven tool and marketing channel for increasing POS sales productivity by implementing digital features to the in-store purchasing experience.

    While LBM is a largely fragmented and budding start-up scene, beaconsmind differentiates in many ways compared to relevant competitors:

    • unique one-stop-shop featuring hardware and software;
    • focus on retail with an actionable and plug-and-play solution;
    • customized beacon solution requiring no maintenance;
    • one of the first global roll-outs in an emerging industry with Adidas seeking to equip up to 15k POS worldwide with the beaconsmindsolution.

    The podcast guests and host will discuss questions like?

    • Foundation of a novel company
    • Key Milestones in beaconsmind corporate development
    • Benefits of an IPO in Europe
    • beaconsmind solutions
    • The future of Commerce

    Interested?

    Link to the Video of the Recording:
    YouTube

    Speaker:
    Christian Soschner
    Max Weiland

    Organizations:
    CS Life Science Invest
    beaconsmind

    Send us Fan Mail

    Support the show

    Join the Podcast Newsletter: Link

    Your Next Move: Link

    1 hr 14 min
  • #39: All You Need to Know About the Novel €95.5 Billion Horizon Europe Programme...

    This podcast episode will discuss the EU’s next framework program for research and innovation, Horizon Europe, and the exciting opportunities this program offers businesses, scientists, and investors. With the launch of the Horizon Europe program just weeks away, we will share insight into the program's novelties, where to start, and tips on how to be successful. 

    The Podcast Host, guests Kimberly Cornfield and Michael Browne will discuss questions like:

    • What is new in Horizon Europe? The European Innovation Council, Missions and Clusters – all you need to know
    • Funding for DeepTech? The opportunities for high-risk/high gain and interdisciplinary research and innovation collaboration
    • Where, when, and how to apply for Horizon Europe funding? – tips from the experts

    We shall address all these questions and discuss the latest priorities in EU research and innovation funding and the importance of collaboration.

    Our guests in this episode:

    Kimberly Cornfield is Head of European Research and Innovation at University College London (UCL), one of the top-performing universities under the EU’s Horizon 2020 program, having secured ca. €400 million over the last seven years to support its research and innovation activities. To support UCL in upholding its place as one of the leading universities in the next EU research and innovation program, Horizon Europe, and achieving its impact objectives, Kimberly and her team connect scientists and business around EU collaborative funding opportunities and offer a suite of support services to improve the chances of success in obtaining funding and achieving their impact objectives.

    Michael Browne is Director and Co-founder at Crowdhelix - an Open Innovation Platform that forges links between an international network of excellent researchers and innovating companies to help deliver pioneering collaborative projects. Michael has worked in the European Research & Innovation space for more than 15 years and is a recognized expert in Framework Programme funding.

    Host:
    Christian Soschner

    Link to the Video of the Recording:

    Youtube Video

    Be part of our Network:
    Subscribe here:  Link

    Send us Fan Mail

    Support the show

    Join the Podcast Newsletter: Link

    Your Next Move: Link

    1 hr 7 min
  • #38: Dusica Lukac - The Magic of Corporate Finance

    In this podcast episode, we will discuss several different forms of growth and scaling up companies. In the era of the fast-growing unicorns and skyrocketing valuations, we try to disassemble the growth path and see what a founder can do to benefit most of these options. 

    • How to decide if an organic or buy&build model is the right one for me? 
    • Are mergers & acquisitions play-field only for the very mature companies? 
    • When is the time to start with bolt-on acquisitions? 
    • Is fast growth really possible in only an organic way? 
    • We shall address all these questions, look into the latest M&A trends of 2020 and 2021, shed a light on the life science industry, and discuss several real-life cases of buy&build growth models. 

    As we are excited about the next podcast episode let us just say ‘Hopin' our podcast episode for more. 

    Dusica Lukac holds an Executive MBA from Carlson Business School, Minnesota, the US and Wirtschaft Universitaet Wien, Vienna, Austria: Entrepreneurial Specialization and Fintech Law and Regulations courses Duke University, US; Private Equity and Venture Capital course Bocconi, Italy.

    Traveled to 78 countries, multilingual, fascinated with financial innovation, watercolor painter.

    Link to the Video of the Recording:
    YouTube

    Speaker:
    Astrid Woollard
    Christian Soschner
    Dusica H. Lukac

    Organizations:
    CS Life Science Invest
    DL Capital Partners Ltd
    XenoVC

    Be part of our Network:
    Subscribe here:  Link

    Send us Fan Mail

    Support the show

    Join the Podcast Newsletter: Link

    Your Next Move: Link

    1 hr 30 min
  • #37: Ana Trbovich - Peer-to-Peer Energy Trading

    In this podcast episode, we will discuss how blockchain technology is utilized in the energy sector beyond the well-known utility of a payments system, her experiences in entrepreneurship and innovation, including start-up life in Berlin.

    Ana Trbovich is the Grid Singularity co-founder & COO and Vice-Chair of the Energy Web Foundation. She serves on UNECE Carbon Neutrality and DENA SET Hub Advisory Boards, and previously acted as an independent board member at the European Institute for Innovation and Technology (EIT), Axa, and the Belgrade Philharmonic, among others. She teaches Entrepreneurship at FEFA, a leading business school in Belgrade, Serbia, where she also served as Dean from 2012 to 2015. She has consulted on good governance, competitiveness, and innovation policy for international organizations, including the EU and the World Bank.

    Link to the Video of the Recording:
    YouTube

    Speaker:
    Ana Trbovich
    Astrid Woollard
    Christian Soschner

    Organizations:
    CS Life Science Invest
    Grid Singularity
    Scytale Ventures


    Be part of our Network:
    Subscribe here:  https://mailchi.mp/e2467061ef75/lsg2g


    Send us Fan Mail

    Support the show

    Join the Podcast Newsletter: Link

    Your Next Move: Link

    1 hr 10 min
  • #36: Secrets of Life Science Investments - An Introduction to Hadean Ventures

    It was great fun to talk with Walter Stockinger, Co-Founder of Hadean Ventures, about the topic of Life Science Investments.

    We covered the following questions:

    • How do Venture Funds operate?
    • What do you need to know about approaching VCs?
    • What is the purpose of a VC?
    • Why are exits necessary for VCs?
    • And what exit strategies are relevant?
    • Why do VCs raise money, and from whom?


    Use the opportunity to get your answer directly from a VC.

    Link to the Video of the Recording:
    YouTube

    Speaker:
    Astrid Woollard
    Christian Soschner
    Walter Stockinger

    Organizations:
    CS Life Science Invest
    Hadean Ventures
    Scytale Ventures


    Be part of our Network:
    Subscribe here:  https://mailchi.mp/e2467061ef75/lsg2g

    Send us Fan Mail

    Support the show

    Join the Podcast Newsletter: Link

    Your Next Move: Link

    50 min
  • #35: Why You Don’t Need to Quit Your Job to Be an Entrepreneur

    This one is an episode for the go-getters and never-giveupers.

    Astrid and Christian had great fun talking with Essa Saulat, Chief Growth Officer of the Austrian digital health company Symptoma.

    Essa is a seasoned entrepreneur and helped many start-ups getting off the ground.

    In this episode, he shares his life story of overcoming adversity, keeping moving forward relentlessly, and ultimately changing his world and the worlds of many people he met in his life for the better.

    He shares in unambiguous words the most important question every entrepreneur needs to confront frequently.

    When you look at the most successful founders and companies globally, they all have clarity and a strong answer to this key question of entrepreneurship.

    Enjoy the show.

    Link to the Video of the Recording:
    YouTube

    Speaker:
    Astrid Woollard
    Christian Soschner
    Essa Saulat

    Organizations:
    CS Life Science Invest
    Scytale Ventures
    Symptoma

    Be part of our Network:
    Subscribe here:  https://mailchi.mp/e2467061ef75/lsg2g

    Send us Fan Mail

    Support the show

    Join the Podcast Newsletter: Link

    Your Next Move: Link

    2 hr 6 min
  • #34: Sascha Bucher - Deal Structuring With the Pharma Industry - From the Investors Perspective

    Drug Development is a challenging process. It needs profound basic research, translating scientific results into products and moving them towards the market.

    Making things more challenging deal structuring is also a b2b business, which means selling products to the pharma industry that completes the product development and brings therapeutics to patients.

    How does structuring deals with the pharma industry really work to sign one of those multi-billion dollar contracts?

    Sascha Bucher is a Venture Capital expert with tremendous experience in deal structuring with the pharmaceutical industry.

    In his career at renowned venture funds and companies like Roivant Sciences, Roche, or UBS, he completed transactions worth more than 10 billion dollars.

    To give life science entrepreneurs access to the expertise, network, and funding, he and his team are in the process of founding Forty51 Ventures - a novel venture fund dedicated to closing the Life Science Valley of Death in Central Europe.

    Join our conversation and learn more about how to negotiate with the pharmaceutical industry.

    Gain more insights into VCs' daily business life with a particular focus on building relationships with BD, R&D, and C-suite executives in the industry.

    Link to the Video of the Recording:
    YouTube

    Speaker:
    Astrid Woollard
    Christian Soschner
    Sascha Bucher

    Organizations:
    CS Life Science Invest
    Forty51 Ventures
    Scytale Ventures

    Send us Fan Mail

    Support the show

    Join the Podcast Newsletter: Link

    Your Next Move: Link

    1 hr 10 min
  • #33: Paul Kohlhaas (Molecule) - Can Blockchain Fund the Biotech Valley of Death?

    Out of 10,000 drug candidates, one reaches patients.

    Most of the others die early, in the stretch between a university lab and a company anyone will fund. Grant money stops there. Venture capital arrives later, and a ticket below 5 million rarely interests it.

    Paul Kohlhaas is CEO of Molecule, a company building a marketplace for early drug development. He came to biotech through biohacking forums, an economics degree in Switzerland, Bitcoin, and years at ConsenSys working on data marketplaces.

    Astrid Woollard of Scytale Ventures joins me as co-host. Paul's idea is to split the ownership of a single patent the way stock markets split the ownership of companies, then let researchers, investors, contract labs and patients each take a share. I push on the hard part. Tech transfer, special purpose vehicles and outsourced research are already standard practice. What does blockchain add?

    Recorded in December 2020.

    WHAT YOU WILL LEARN

    • Why Paul calls pharma one of the last big pipeline businesses, and what Uber did to taxis
    • How shared, token-based ownership of intellectual property (IP) works for one preclinical asset
    • Why a traded asset pays scientists to publish negative data before a pharma company spends 200 million on a failed Phase 2 trial
    • How a pharma company buys out an asset held by thousands of token holders
    • How a contract research organization (CRO) can trade lab work for a share of the asset

    BEST QUOTES

    • (00:01:50) "Pharma is really one of the last big pipeline models."
    • (00:13:14) "With the current way that IP and patents are monopolized, negative data is not valuable."
    • (00:28:36) "You need a minimum income of 200k a year or over 1 million in assets. That's most of your research community and most of your patient groups gone."
    • (00:39:56) "What if you had a new diabetic treatment that was funded by patients?"
    • (01:21:35) "In some parts it's outright a bit crazy, but you need that kind of mentality if you really want to make big changes to the system."

    TIMESTAMPS

    THE VALLEY OF DEATH

    • (00:00:00) Intro, 10,000 candidates and one medicine
    • (00:01:50) From biohacking forums to Bitcoin to Molecule

    TOKENIZING A PATENT

    • (00:06:51) Splitting a patent the way stock markets split companies
    • (00:13:14) A bounty for negative data
    • (00:17:28) Where insider trading starts on an open compound

    THE HARD QUESTIONS

    • (00:20:26) Why bring a patent to this market
    • (00:23:13) Pre-seed, the stage where grants stop and VCs wait
    • (00:27:43) Tech transfer already works, what does blockchain add
    • (00:34:51) Banking APIs and money that moves in seconds

    NEW OWNERS, NEW MARKETS

    • (00:39:56) Patients and researchers as investors
    • (00:47:00) Payment, asset and utility tokens, and the decentralized autonomous organization (DAO)
    • (00:51:33) When pharma wants to buy the whole asset
    • (00:53:47) Kira Borchert asks where the liquidity comes from

    LICENSING, FEES AND SCALE

    • (00:55:30) IP strategy and university licensing templates from the 1980s
    • (01:00:37) A fairer drug system and a success fee model
    • (01:13:49) What the Wellcome Trust makes of tokens

    THE WONDER QUESTION

    • (01:15:48) The wonder question, Molecule at full scale
    • (01:17:26) Robotic labs that work for tokens
    • (01:19:41) A token holder vote that closes a deal in two weeks
    • (01:25:15) Closing thoughts

    Molecule: https://www.molecule.to/
    Video of the recording: https://youtu.be/hUdd6kfpa_k
    Newsletter: https://lsg2g.substack.com/

    Follow Beginner's Mind for long-form conversations on leadership, capital, technology, and the people building what comes next.

    Ranked in the global top 10% of all podcasts, named #1 Deep Tech Podcast in 2025, and #8 Deep Tech Podcast in 2026

    Send us Fan Mail

    Support the show

    Join the Podcast Newsletter: Link

    Your Next Move: Link

    1 hr 28 min
  • #32: Tax & Funding Update 2021 - Tech in Austria – Ask the Tax Experts of KPMG Austria

    A new year brings new tax rules.

    Astrid Woollard and Christian Soschner asked the Tax Experts of KPMG Austria to give an update on the newest regulations in Austria.

    We also had a chance to talk about tax advisors and auditors' roles in the start-up economy.

    Listen to this episode to learn what's new and when to consult advisors.

    If you have questions after listening to the episode, reach out to Michael and Oliver.

    For the videophile:
    The Video to the Podcast

    Resources mentioned in the podcast:
    Research Premium and its role in Fundraising
    Government and institution measures in response to COVID-19
    COVID-19 Tax Info (in German)
    Folge #099: Tax Hacks & Fun Stuff aus der Start-up-Beratungspraxis (in German)

    Speaker:
    Astrid Woollard
    Christian Soschner
    Michael Klewan
    Oliver Mavher

    Organizations:
    CS Life Science Invest
    KPMG Austria
    Scytale Ventures

    Show Notes:
    00:11:27 Home Office and Taxation
    00:14:34 Funding and SMEs
    00:17:44  Solvency and Zombie Companies
    00:20:54 Cryptocurrency
    00:24:41 The Role of Tax Consultants and Auditors in Start-Up Companies
    00:31:58 AI in Bookkeeping
    00:36:00 Secrets of Auditing in the Start-Up World
    00:44:12 Wirecard and Auditing
    00:54:40 Tax Deadlines and Tax Breaks in 2021
    01:04:14 Research Premium and SAAS
    01:26:17 Critical Deadlines in 2021
    01:29:00 Tax Loss Carry Backwards
    01:34:00 New VC Fund for Start-Ups in Austria
    01:38:00 Invitation to Reach Out to Michael and Oliver.



    Be part of our Network:
    Subscribe here:  https://mailchi.mp/e2467061ef75/lsg2g

    Send us Fan Mail

    Support the show

    Join the Podcast Newsletter: Link

    Your Next Move: Link

    1 hr 42 min